Every 10-Q that HYPHA LABS, INC. (FUNI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow FUNI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FUNI filings page.
Hypha Labs, Inc. is a Nevada company developing the Hypha Micropearl bioreactor, a home device to grow functional mushroom “Micropearls,” after exiting its cannabis testing lab business in February 2024. For the quarter ended June 30, 2026, it generated no revenue and reported a net loss of $304,757, improving from a loss of $562,023 a year earlier. For the nine months, the net loss was $1,347,509 versus $2,543,486 in the prior-year period, driven by sharply lower stock-based compensation and professional fees.
Cash declined to $5,110 with total assets of $68,327 against current liabilities of $1,592,630 and total liabilities of $3,155,687, resulting in a stockholders’ deficit of $3,420,960. Management disclosed substantial doubt about the company’s ability to continue as a going concern due to negative working capital, recurring losses, and minimal cash. The company funded operations mainly through new debt and equity, including $155,000 of new convertible notes, $152,500 of new notes payable, and net proceeds of $57,485 from Series D preferred units, while recording a new derivative liability of $154,935 associated with a defaulted note. After quarter-end, it raised $85,000 by selling rights to an Invictus promissory note.
Hypha Labs, Inc. reported no revenue for the three and six months ended March 31, 2026 and remains pre-commercial as it pivots from cannabis testing to its Hypha Micropearl mushroom bioreactor business. The company posted a net loss of $521,114 for the quarter and $1,042,752 for six months.
At March 31, 2026, Hypha held $82,200 of cash, total assets of $159,819, total liabilities of $2,942,422, and a stockholders’ deficit of $3,116,203. Management disclosed negative working capital of $1,338,365 and an accumulated deficit of $24,692,079, and stated these factors raise substantial doubt about its ability to continue as a going concern.
To fund operations, Hypha raised $150,000 through a new senior secured convertible note, $102,500 from notes payable, and net proceeds of $57,484 from sales of Series D Preferred units under a Regulation A offering, while also converting $90,000 of debt into equity. Interest expense rose sharply to $147,339 for the six months, reflecting higher note and convertible note balances.
Hypha Labs, Inc. reported unaudited results for the three months ended December 31, 2025 with no revenue and a net loss of $521,638, an improvement from a $1,339,641 loss a year earlier. Operating expenses fell sharply as prior-period stock-based compensation dropped.
At December 31, 2025, the company had cash of $42,854, negative working capital of $1,006,193, total liabilities of $2,743,090 and a stockholders’ deficit of $2,685,089. Management states these conditions raise substantial doubt about its ability to continue as a going concern.
Hypha has exited cannabis testing and is developing its Hypha Micropearl bioreactor for at-home functional mushroom production. To support this shift, it relies on debt and equity financing, including $57,485 of net proceeds from a Regulation A offering of Series D preferred stock and warrants during the quarter, alongside increased notes and convertible notes payable.